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This thesis presents computational methods used for the recognition of
disease genes and for the optimal design of disease gene CRISPR/Cas9
editing systems. The key innovation in these computational methods is
the feature space and characteristics captured from the biology domain
knowledge through machine learning algorithms.
The disease-gene association prediction problems are studied in Chapters
3-5. Disease gene recognition is a hot topic in various fields, especially in
biology, medicine and pharmacology. Non-coding genes, a type of genes
without protein products, have been proved to play important roles in disease
development. Particularly, the two kinds of non-coding gene products such
as microRNA (miRNA) and long non-coding RNA (lncRNA) have caught
much attention as they are abundantly expressed in various tissues and
frequently interact with other biomolecules, e.g. DNA, RNA and protein.
The disease-ncRNA relationships remain largely unknown. Computational
methods can immensely help replenish this kind of knowledge. To overcome
existing computational methods’ limitations such as significantly relying on
network structures and similarity measurements, or lacking reliable negative
samples, this thesis presents two novel methods.
One is the precomputed kernel matrix support vector machine (SVM)
method to predict disease related miRNAs in Chapter 3. The precomputed
kernel matrix was built by integrating several kinds of similarities computed
with effective characteristics for miRNAs and diseases. The reliable negative
samples were collected through analyzing the published array and sequencing
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data. This binary classification method accurately predicts disease-miRNA
associations, which outperforms those state-of-the-art methods. In Chapter
4, the predicted novel disease-miRNA associations were combined with
known relationships of diseases, miRNAs and genes to reconstruct a disease-
gene-miRNA (DGR) tripartite network. Reliable multi-disease associated
co-functional miRNA pairs were extracted from this DGR for cross-disease
analysis by defining the co-function score. This not only proves the proposed
method’s effectiveness but also contributes to the study of multi-purpose
miRNA therapeutics.
Another is the bagging SVM-based positive-unlabeled learning method
for disease-lncRNA prioritizing that is described in Chapter 5. It creatively
characterized a disease with its related genes’ chromosome distribution and
pathway enrichment properties. The disease-lncRNA pairs were represented
as novel feature vectors to train the bagging SVM for predicting disease-
lncRNA associations. This novel representation contributes to the superior
performance of the proposed method in disease-lncRNA prediction even when
a given disease has no currently recognized lncRNA genes.
After confirming the relationships between genes and diseases, one of the
most difficult tasks is to investigate the molecular mechanism and treatment
of the diseases considering their related genes. The CRISPR/Cas9 system
is a promising gene editing tool for operating the genes to achieve the goals
of disease-gene function clarification and genetic disease curing. Designing
an optimal CRISPR/Cas9 system can not only improve its editing efficiency
but also reduce its side effect, i.e. off-target editing. Furthermore, the off-
target site detection problem involves genome-wide sequence observing which
makes it a more challenging job. The CRISPR/Cas9 system on-target cutting
efficiency prediction and off-target site detection questions are discussed in
Chapters 6 and 7 respectively.
To accurately measure the CRISPR/Cas9 system’s cutting efficiency,
the profiled Markov properties and some cutting position related features
were merged into the feature space for representing the single-guide RNAs
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(sgRNAs). These features were learned by a two-step averaging method
where an XGBoost’s predictions and an SVM’s predictions were averaged
as the final results. Later performance evaluations and comparisons
demonstrate that this method can predict a sgRNA’s cutting efficiency with
consistently good performance no matter it is expressed from a U6 promoter
in cells or from a T7 promoter in vitro.
In the off-target site detection, a sample was defined as an on-target-off-
target site sequence pair to turn this problem into a classification issue. Each
sample was numerically depicted with the nucleotide composition change
features and the mismatch distribution properties. An ensemble classifier
was constructed to distinguish real off-target sites and no-editing sites of a
given sgRNA. Its excellent performance was confirmed with different test
scenarios and case studies.
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